Related Experiment Video
Updated: May 11, 2026
Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
Efficacy of a pneumococcal conjugate vaccine against acute otitis media
Insights
A new heptavalent pneumococcal conjugate vaccine (PCV) shows promise in preventing ear infections. The PCV significantly reduced Streptococcus pneumoniae-related acute otitis media episodes in infants, demonstrating its efficacy and safety.
Area of Science:
- Pediatrics
- Immunology
- Vaccinology
Background:
- Acute otitis media (AOM) is a frequent childhood illness, particularly in the first two years of life.
- Streptococcus pneumoniae is a primary bacterial cause of AOM.
- Pneumococcal conjugate vaccines offer a potential strategy for AOM prevention.
Purpose of the Study:
- To evaluate the efficacy and safety of a heptavalent pneumococcal polysaccharide conjugate vaccine (CRM197 carrier protein) in preventing AOM in infants.
- To assess the vaccine's impact on culture-confirmed pneumococcal AOM and AOM caused by specific serotypes.
Main Methods:
- A randomized, double-blind, placebo-controlled efficacy trial involving 1662 infants.
- Infants received either the pneumococcal conjugate vaccine or a hepatitis B control vaccine at 2, 4, 6, and 12 months of age.
- AOM diagnosis was based on clinical criteria and middle-ear fluid cultures.
Main Results:
- The vaccine demonstrated a 34% reduction in culture-confirmed pneumococcal AOM episodes (95% CI, 21-45%).
- Episodes caused by vaccine serotypes decreased by 57% (95% CI, 44-67%).
- Local reactions were more frequent than with the control but less than with other routine infant vaccines.
Conclusions:
- The heptavalent pneumococcal polysaccharide-CRM197 conjugate vaccine is safe and effective for preventing AOM caused by vaccine serotypes.
- The vaccine significantly reduces the burden of pneumococcal AOM in infants.
Background:
Ear infections are a common cause of illness during the first two years of life. New conjugate vaccines may be able to prevent a substantial portion of cases of acute otitis media caused by Streptococcus pneumoniae.
Methods:
We enrolled 1662 infants in a randomized, double-blind efficacy trial of a heptavalent pneumococcal polysaccharide conjugate vaccine in which the carrier protein is the nontoxic diphtheria-toxin analogue CRM197. The children received either the study vaccine or a hepatitis B vaccine as a control at 2, 4, 6, and 12 months of age. The clinical diagnosis of acute otitis media was based on predefined criteria, and the bacteriologic diagnosis was based on a culture of middle-ear fluid obtained by myringotomy.
Results:
Of the children who were enrolled, 95.1 percent completed the trial. With the pneumococcal vaccine, there were more local reactions than with the hepatitis B vaccine but fewer than with the combined whole-cell diphtheria-tetanus-pertussis and Haemophilus influenzae type b vaccine that was administered simultaneously. There were 2596 episodes of acute otitis media during the follow-up period between 6.5 and 24 months of age. The vaccine reduced the number of episodes of acute otitis media from any cause by 6 percent (95 percent confidence interval, -4 to 16 percent [the negative number indicates a possible increase in the number of episodes]), culture-confirmed pneumococcal episodes by 34 percent (95 percent confidence interval, 21 to 45 percent), and the number of episodes due to the serotypes contained in the vaccine by 57 percent (95 percent confidence interval, 44 to 67 percent). The number of episodes attributed to serotypes that are cross-reactive with those in the vaccine was reduced by 51 percent, whereas the number of episodes due to all other serotypes increased by 33 percent.
Conclusions:
The heptavalent pneumococcal polysaccharide-CRM197 conjugate vaccine is safe and efficacious in the prevention of acute otitis media caused by the serotypes included in the vaccine.
More Related Videos
Related Concept Videos
01:30Acute Pharyngitis
Acute pharyngitis is the inflammation of the back of the throat (pharynx), commonly resulting in a sore throat. It is a frequently encountered condition that prompts individuals to seek medical advice.
Classification
Acute pharyngitis can be categorized based on its underlying cause:
01:29Pneumonia II: Pathophysiology
01:30Pneumonia III: Complications and Assessment
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:30Pneumonia V: Nursing management and Prevention
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed.
01:28Antimicrobial Effectiveness